{"url_path":"/sec/tara/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055462-index.html","accession_number":"0001213900-26-055462","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-055462-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n99.1\n \n[Press Release dated May 13, 2026, issued by the Registrant.](ea028858101ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n1\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange\nAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**PROTARA THERAPEUTICS, INC.**\n\n \n \n \n\nDate: May 13, 2026\nBy:\n/s/ Patrick Fabbio\n\n \n \nPatrick Fabbio\n\n \n \n*Chief Financial Officer*\n\n \n\n2"}